Keith Crandell
Keith Crandell's purchase track record
Keith Crandell has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/2/2024 | BOLD | $3.20M | -68.4% | -76.1% | +9.7% |
| 2/8/2024 | SANA | $10.00M | +21.8% | -24.3% | +6.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Twist Bioscience highlighted in AI biofoundry and analyst upgrades. Recent coverage places Twist Bioscience at the center of AI‑driven biofoundry platforms and synthetic antibody library development. Analyst TD Cowen raised its price target to $190, reflecting confidence in the company’s role in these growing markets. The stock also appeared in a portfolio update and a whale‑alert list, indicating heightened investor attention.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Sana Biotechnology Featured in Diabetes Treatment Analysis. Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Quanterix Highlights Spatial Biology Innovation at ESSB 2026. Quanterix announced it met its spatial biology content innovation commitments during the ESSB 2026 event. The company showcased new tools and data sets that support advanced spatial analysis. This demonstrates progress in its product roadmap and may strengthen its position in the spatial biology market.
Transaction History
| BOLD | ▲ Buy | Option Exercise | 16,000 | $16K | 7/1/2026 | View on chart |
| BOLD | ▼ Sell | Open Market | 16,000 | $40K | 7/1/2026 | View on chart |
| MASS | ▲ Buy | Option Exercise | 14,083 | — | 6/10/2026 | View on chart |
| TWST | ▲ Buy | Grant | 5,095 | $0 | 2/5/2026 | View on chart |
| MASS | ▲ Buy | Option Exercise | 11,364 | — | 6/11/2025 | View on chart |
| TWST | ▲ Buy | Grant | 4,472 | $0 | 2/5/2025 | View on chart |
| MASS | ▲ Buy | Option Exercise | 7,777 | — | 6/12/2024 | View on chart |
| BOLD | ▼ Sell | Other | 589,743 | — | 4/2/2024 | View on chart |
| BOLD | ▼ Sell | Other | 787,545 | — | 4/2/2024 | View on chart |
| BOLD | ▼ Sell | Other | 1,048,433 | — | 4/2/2024 | View on chart |
| BOLD | ▲ Buy | Open Market | 66,667 | $1.1M | 4/2/2024 | View on chart |
| BOLD | ▲ Buy | Open Market | 133,333 | $2.1M | 4/2/2024 | View on chart |
| SANA | ▲ Buy | Open Market | 363,637 | $2.0M | 2/8/2024 | View on chart |
| SANA | ▲ Buy | Open Market | 727,272 | $4.0M | 2/8/2024 | View on chart |
| SANA | ▲ Buy | Open Market | 727,272 | $4.0M | 2/8/2024 | View on chart |
| TWST | ▲ Buy | Grant | 5,815 | $0 | 2/6/2024 | View on chart |
| MASS | ▲ Buy | Option Exercise | 4,771 | — | 6/14/2023 | View on chart |
| QTRX | ▲ Buy | Grant | 1,170 | $13K | 4/3/2023 | View on chart |
| TWST | ▲ Buy | Grant | 8,212 | $0 | 2/7/2023 | View on chart |
| QTRX | ▲ Buy | Grant | 1,015 | $13K | 1/3/2023 | View on chart |
| QTRX | ▲ Buy | Grant | 8,083 | $0 | 1/3/2023 | View on chart |
| QTRX | ▲ Buy | Grant | 1,326 | $14K | 10/3/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 893 | $15K | 7/1/2022 | View on chart |
| MASS | ▲ Buy | Option Exercise | 1,379 | — | 6/15/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 492 | $15K | 4/1/2022 | View on chart |
| TWST | ▲ Buy | Grant | 3,491 | $0 | 2/8/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 307 | $13K | 1/3/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 2,668 | $0 | 1/3/2022 | View on chart |
| QTRX | ▼ Sell | Other | 177,247 | $0 | 11/18/2021 | View on chart |
| QTRX | ▼ Sell | Other | 9,318 | $0 | 11/18/2021 | View on chart |
| QTRX | ▼ Sell | Other | 113,003 | $0 | 11/18/2021 | View on chart |
| QTRX | ▼ Sell | Other | 9,952 | $0 | 11/16/2021 | View on chart |
| QTRX | ▼ Sell | Other | 120,689 | $0 | 11/16/2021 | View on chart |
| QTRX | ▼ Sell | Other | 189,311 | $0 | 11/16/2021 | View on chart |
| QTRX | ▲ Buy | Grant | 254 | $13K | 10/1/2021 | View on chart |
| QTRX | ▼ Sell | Other | 120,689 | $0 | 8/17/2021 | View on chart |
| QTRX | ▼ Sell | Other | 9,954 | $0 | 8/17/2021 | View on chart |
| QTRX | ▼ Sell | Other | 189,311 | $0 | 8/17/2021 | View on chart |
| QTRX | ▼ Sell | Other | 9,952 | $0 | 8/10/2021 | View on chart |
| QTRX | ▼ Sell | Other | 120,689 | $0 | 8/10/2021 | View on chart |
| QTRX | ▼ Sell | Other | 189,311 | $0 | 8/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
BOLD trades near support amid sector news
Recent headlines focus on Beam Therapeutics and Callio Therapeutics rather than direct developments for Boundless Bio. The stock is currently trading near its identified support level, with technical indicators showing a breakdown signal. Analysts maintain a single price target of $4.00, which sits above the current trading range.
BOLD trades near support amid sector news. Recent headlines focus on Beam Therapeutics and Callio Therapeutics rather than direct developments for Boundless Bio. The stock is currently trading near its identified support level, with technical indicators showing a breakdown signal. Analysts maintain a single price target of $4.00, which sits above the current trading range.